Neuroleptic-in duced cata to nia (NIC) is an un com mon se vere extrapyramidal reac tion char ac ter ized by iso la tion, mutism, neg a tiv ism, ri gid ity, im mo bility, and waxy flex i bil ity with out se vere hyperthermia and au to nomic al ter ation. It has tra di tion ally been as so ci ated with high-po tency neuroleptics (for ex am ple haloperidol) and their do pa mine-blocking prop er ties (1). Sev eral au thors are prone to con sider NIC and the neuroleptic ma lig nant syn drome (NMS) as con di tions that are part of the same neuroleptic-tox ic ity spec trum, where NIC is an ini tial stage that pro gresses to NMS (1, 2) . With re gard to the new est atyp i cal neuroleptics, a case of NIC second ary to risperidone treat ment has been re ported (3), while sev eral cases of NMS sec ond ary to clozapine use (4), and a case of ex cited cata to nia af ter abrupt clozapine with drawal (5), have been de scribed.
Neuroleptic-in duced cata to nia (NIC) is an un com mon se vere extrapyramidal reac tion char ac ter ized by iso la tion, mutism, neg a tiv ism, ri gid ity, im mo bility, and waxy flex i bil ity with out se vere hyperthermia and au to nomic al ter ation. It has tra di tion ally been as so ci ated with high-po tency neuroleptics (for ex am ple haloperidol) and their do pa mine-blocking prop er ties (1) . Sev eral au thors are prone to con sider NIC and the neuroleptic ma lig nant syn drome (NMS) as con di tions that are part of the same neuroleptic-tox ic ity spec trum, where NIC is an ini tial stage that pro gresses to NMS (1, 2) . With re gard to the new est atyp i cal neuroleptics, a case of NIC second ary to risperidone treat ment has been re ported (3), while sev eral cases of NMS sec ond ary to clozapine use (4), and a case of ex cited cata to nia af ter abrupt clozapine with drawal (5), have been de scribed.
To our knowl edge, this is the first case of typ i cal cata tonic syn drome, with out signs of NMS, con com i tant to clozapine treat ment.
Case Re port
Mrs AR is a 36-year-old woman with a 20-year di ag no sis of dis or ga nized schizo phre nia. She has been re peat edly ad mit ted to psy chi at ric units and treated with dif fer ent classes of neuroleptics (that is, haloperidol, risperidone, and olanzapine) with par tial clin i cal response but no cata tonic symp toms.
Dur ing one of her ad mis sions, a trial of clozapine 25 mg daily was started. Routine lab o ra tory tests (that is, com plete blood count, hematocrit, elec tro lytes, transaminases, and creatinine) were normal, and there were no signs of au tonomic dys func tion. In the next 2 weeks, the dos age of clozapine was ti trated to 250 mg daily. Grad ually, her psy chotic symp toms im proved, but re duced mo tor and ver bal re sponses ap peared. Typ i cal cata tonic symp toms (that is, iso la tion, pos tur ing, mutism, neg a tiv ism, and waxy flex i bil ity) with mild ri gid ity were pres ent dur ing the next few days (19 days af ter clozapine ini ti a tion). The patient was apyretic, not di a pho retic. Heart rate, blood pres sure, lab o ra tory tests (blood count, urine, and liver func tions), and creatine phosphokinase (CPK) (89 IU/L) re mained in the nor mal range. Because clin i cal in ves ti ga tions failed to reveal any other pos si ble med i cal cause, there was no his tory of past cata tonic epi sodes, and symp toms oc curred af ter initi a tion of clozapine, NIC sec ond ary to clozapine was hy poth e sized. Ac cord ing to treat ment guide lines for the NIC (1), clozapine was dis con tin ued, and lorazepam 7.5 mg daily was started.
In the fol low ing days, we ob served a quick im prove ment of the pa tient's condi tion (that is, de creased pos tur ing, mutism, waxy flex i bil ity, and mus cu lar ri gid ity), with com plete re mis sion af ter 5 days. Rechallenge with clozapine was not tried be cause the pa tient re fused to re peat treat ment.
We have de scribed the case of sus pected clozapine-in duced cata to nia in a pa tient with schizo phre nia. This pa tient had no past his tory of cata to nia but slowly de vel oped typ i cal cata tonic symp toms, with out ver i fi able med i cal causes, af ter low dos ages of clozapine were ini ti ated. She im proved dra mat i cally af ter the drug was stopped. This case seems to sup port the pos si bil ity that the atyp i cal neuroleptics may also be in volved in the cause of NIC.
Ac cord ing to the pro posed stag ing system of the NIC-NMS spec trum (2) , this case could be con sid ered as a mild form of NIC-NMS. Given the atyp i cal charac ter is tics of clozapine-in duced NMS (for ex am ple, the lack of ri gid ity, tremor, or fe ver) (4), the risk of un der esti mat ing the pro gres sion from NIC to NMS is to be con sid ered.
Al though fur ther re search is nec es sary, cli ni cians should be aware of the pos sible re la tion be tween cata tonic syn drome and novel antipsychotics with weak dopa mine-block ing prop er ties, such as clozapine.
